US-based medical device company Reflow Medical has secured approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its Wingman Cross Chronic Total Occlusions (CTO) Catheter.

The company partnered with Tokyo-based medical device distributor Century Medical (CMI) for the launch of the Wingman CTO Catheter in Japan.

Using an extendable bevelled tip, the Wingman Catheter crosses peripheral CTOs in peripheral artery disease.

Wingman Catheter provides physicians with controls the advancement and activation of the tip to form a channel to help penetrate, or cross, the occlusion with a guidewire, allowing additional treatment of the lesion with therapeutic devices.

PMDA approval derives from Wing-IT CTO clinical trial that treated 85 patients and followed them for a period of 30 days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Wing-IT CTO clinical trial is a prospective, international, multicenter study reported 90% crossing rate for Reflow’s catheter when up to two previous guidewires could not cross the CTO’s.

CMI president and CEO Takahiko Motani said: “We are very excited to launch the Wingman CTO catheter in the Japanese market. This product should have a significant impact on the Japanese peripheral market by helping physicians address specific treatment challenges within a growing patient population. We look forward to providing this new and unique device in partnership with Reflow Medical.”

Reflow Medical co-founder and CEO Isa Rizk added: “It is an honour for our device to have gained approval by Japan’s PMDA. We are grateful for the opportunity to partner with a fantastic organisation like Century Medical.”

In March, the US Food and Drug Administration (FDA) cleared the catheter for the expanded CTO indication, following the completion of the Wing-IT clinical trial.

Earlier, in January, the company obtained breakthrough device designation for its Temporary Spur Stent System from the FDA.